NASDAQ:REGN

Regeneron Pharmaceuticals - REGN Stock Forecast, Price & News

$738.14

-4.69 (-0.63%)

(As of 01/30/2023 12:26 PM ET)

Add

Compare

Today's Range: $737.57
▼
$749.00
50-Day Range: $680.49
▼
$766.39
52-Week Range: $538.01
▼
$779.00

Volume: 137,450 shs
Average Volume: 591,587 shs
Market Capitalization: $80.38 billion

P/E Ratio: 15.56
Dividend Yield: N/A
Price Target: $786.15

Institutional Ownership

Regeneron Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.65 Rating Score
Upside/Downside: 6.8% Upside
$792.40 Price Target
Short Interest: Healthy
1.38% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.68
Upright™ Environmental Score
News Sentiment: 0.49
Based on 27 Articles This Week
Insider Trading: Selling Shares
$14.07 M Sold Last Quarter
Proj. Earnings Growth: -3.69%
From $38.24 to $36.83 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

247th out of 1,049 stocks

Pharmaceutical Preparations Industry

119th out of 514 stocks

2.4

Analyst's Opinion

Consensus Rating
Regeneron Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 16 buy ratings, 3 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $792.40, Regeneron Pharmaceuticals has a forecasted upside of 6.8% from its current price of $741.91.
Amount of Analyst Coverage
Regeneron Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
1.38% of the float of Regeneron Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Regeneron Pharmaceuticals has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Regeneron Pharmaceuticals has recently decreased by 6.00%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Regeneron Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Regeneron Pharmaceuticals does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Regeneron Pharmaceuticals has received a 64.79% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Cancer medication (L01)", "Rheumatoid arthritis medication", and "Anakinra" products. See details.
Environmental Sustainability
The Environmental Impact score for Regeneron Pharmaceuticals is -1.68.

2.5

News and Social Media Coverage

News Sentiment
Regeneron Pharmaceuticals has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 27 news articles for Regeneron Pharmaceuticals this week, compared to 9 articles on an average week.
Search Interest
19 people have searched for REGN on MarketBeat in the last 30 days. This is an increase of 171% compared to the previous 30 days.
MarketBeat Follows
Only 8 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -56% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,070,511.00 in company stock.
Percentage Held by Insiders
Only 8.99% of the stock of Regeneron Pharmaceuticals is held by insiders.
Percentage Held by Institutions
84.25% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Regeneron Pharmaceuticals are expected to decrease by -3.69% in the coming year, from $38.24 to $36.83 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Regeneron Pharmaceuticals is 15.64, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 121.05.
Price to Earnings Ratio vs. Sector
The P/E ratio of Regeneron Pharmaceuticals is 15.64, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 88.92.
Price to Earnings Growth Ratio
Regeneron Pharmaceuticals has a PEG Ratio of 2.24. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Regeneron Pharmaceuticals has a P/B Ratio of 4.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Stock News Headlines

January 6, 2023 | marketbeat.com

Four Undervalued Healthcare Stocks for 2023 (REGN)

These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.

January 30, 2023 | americanbankingnews.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Outperform at Cowen

January 30, 2023 | Porter & Company (Ad)

Is This The End of Capitalism?

EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…

January 30, 2023 | americanbankingnews.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Raised to "Outperform" at Cowen

January 30, 2023 | reuters.com

Sanofi and Regeneron's Dupixent wins new European Commission approval

January 30, 2023 | msn.com

Sanofi, Regeneron Dupixent gets approval in EU for expanded use in eosinophilic esophagitis

January 30, 2023 | finance.yahoo.com

Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis

January 28, 2023 | americanbankingnews.com

FY2022 EPS Estimates for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Cut by Analyst

January 30, 2023 | Porter & Company (Ad)

Is This The End of Capitalism?

EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…

January 27, 2023 | finance.yahoo.com

Why Regeneron (REGN) is Poised to Beat Earnings Estimates Again

January 27, 2023 | markets.businessinsider.com

Regeneron Pharma: CHMP Adopts Positive Opinion For Dupixent

January 27, 2023 | finance.yahoo.com

Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

January 27, 2023 | reuters.com

Sanofi's and Regeneron's Dupixent wins new stage of EU regulatory approval

January 27, 2023 | finance.yahoo.com

Dupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP to Treat Children as Young as Six Months Old with Severe Atopic Dermatitis

January 27, 2023 | finance.yahoo.com

UPDATE 1-Sanofi's and Regeneron's Dupixent wins new stage of EU regulatory approval

January 26, 2023 | americanbankingnews.com

Regeneron Pharmaceuticals (NASDAQ:REGN) PT Raised to $873.00 at Morgan Stanley

January 25, 2023 | marketwatch.com

Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day

January 25, 2023 | finance.yahoo.com

12 Cheap Biotech Stocks To Buy

January 24, 2023 | marketwatch.com

Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market

January 24, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Regeneron (REGN) and Revance Therapeutics (RVNC)

January 24, 2023 | finance.yahoo.com

Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation's Oldest and Most Prestigious Science and Math Competition

January 23, 2023 | americanbankingnews.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at JPMorgan Chase & Co.

January 22, 2023 | americanbankingnews.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $782.53 Consensus PT from Analysts

January 22, 2023 | americanbankingnews.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $782.53 Consensus PT from Brokerages

January 19, 2023 | msn.com

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years

January 16, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN) and Teleflex (TFX)

January 16, 2023 | finance.yahoo.com

Why Regeneron's CEO remains bullish on Eylea drug after 11 years on the market

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Company Calendar

Last Earnings: 11/03/2022
Today: 1/30/2023
Next Earnings (Confirmed): 2/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:REGN
CUSIP: 75886F10
CIK: 872589
Web: www.regeneron.com
Phone: (914) 847-7000
Fax: 914-347-2113
Employees: 10,368
Year Founded: 1988

Price Target and Rating

Average Stock Price Forecast: $792.40
High Stock Price Forecast: $970.00
Low Stock Price Forecast: $625.00
Forecasted Upside/Downside: +6.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.65
Research Coverage: 20 Analysts

Profitability

EPS (Most Recent Fiscal Year): $47.43
Trailing P/E Ratio: 15.56
Forward P/E Ratio: 19.30
P/E Growth: 2.24
Net Income: $8.08 billion
Net Margins: 39.17%
Pretax Margin: 44.04%
Return on Equity: 31.16%
Return on Assets: 23.61%

Debt

Debt-to-Equity Ratio: 0.13
Current Ratio: 5.36
Quick Ratio: 4.52

Sales & Book Value

Annual Sales: $16.07 billion
Price / Sales: 5.00
Cash Flow: $80.32 per share
Price / Cash Flow: 9.19
Book Value: $172.92 per share
Price / Book: 4.27

Miscellaneous

Outstanding Shares: 108,900,000
Free Float: 99,112,000
Market Cap: $80.38 billion
Optionable: Optionable
Beta: 0.22

Social Links

Key Executives

Leonard S. Schleifer
Co-President, Chief Executive Officer & Director

George Damis Yancopoulos
Co-President, Director & Chief Scientific Officer

Patrice Gilooly
Senior VP-Quality Assurance & Operations

Robert E. Landry
Chief Financial Officer & Executive VP-Finance

Neil Stahl
Executive VP-Research & Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

REGN Stock - Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?: 20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" REGN shares.
View REGN analyst ratings or view top-rated stocks.
What is Regeneron Pharmaceuticals' stock price forecast for 2023?: 20 equities research analysts have issued 12 month price objectives for Regeneron Pharmaceuticals' stock. Their REGN share price forecasts range from $625.00 to $970.00. On average, they expect the company's share price to reach $792.40 in the next twelve months. This suggests a possible upside of 6.7% from the stock's current price.
View analysts price targets for REGN or view top-rated stocks among Wall Street analysts.
How have REGN shares performed in 2023?: Regeneron Pharmaceuticals' stock was trading at $721.49 on January 1st, 2023. Since then, REGN stock has increased by 3.0% and is now trading at $742.92.
View the best growth stocks for 2023 here.
When is Regeneron Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, February 3rd 2023.
View our REGN earnings forecast.
How can I listen to Regeneron Pharmaceuticals' earnings call?: Regeneron Pharmaceuticals will be holding an earnings conference call on Friday, February 3rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Regeneron Pharmaceuticals' earnings last quarter?: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its earnings results on Thursday, November, 3rd. The biopharmaceutical company reported $9.98 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $8.55 by $1.43. The biopharmaceutical company had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.79 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 31.16% and a net margin of 39.17%.
What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?: 423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).
What is Regeneron Pharmaceuticals' stock symbol?: Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."
Who are Regeneron Pharmaceuticals' major shareholders?: Regeneron Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.35%), New York State Teachers Retirement System (0.11%), Assenagon Asset Management S.A. (0.11%), Pendal Group Ltd (0.11%), Natixis Advisors L.P. (0.10%) and Ardevora Asset Management LLP (0.08%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends.
How do I buy shares of Regeneron Pharmaceuticals?: Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Regeneron Pharmaceuticals' stock price today?: One share of REGN stock can currently be purchased for approximately $742.92.
How much money does Regeneron Pharmaceuticals make?: Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $80.90 billion and generates $16.07 billion in revenue each year. The biopharmaceutical company earns $8.08 billion in net income (profit) each year or $47.43 on an earnings per share basis.
How many employees does Regeneron Pharmaceuticals have?: The company employs 10,368 workers across the globe.
Does Regeneron Pharmaceuticals have any subsidiaries?: The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More
How can I contact Regeneron Pharmaceuticals?: Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for the company is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at invest@regeneron.com, or via fax at 914-347-2113.

This page (NASDAQ:REGN) was last updated on 1/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Regeneron Pharmaceuticals - REGN Stock Forecast, Price & News

Regeneron Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

REGN Stock News Headlines

REGN Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

REGN Stock - Frequently Asked Questions

Overall MarketRank^™